Novartis seeks approval to use Gleevec in four rare cancers

Article Abstract:

Novartis AG of Switzerland has asked for regulatory approval in Europe as well as the United States to sell the drug Gleevec for treatment of four rare cancer types. The four rare cancers are dermatofibrosarcoma protuberans, systemic mastocytosis, hypereosinophilic syndrome and certain myeloproliferative disorders. The move is seen as a shift in cancer care towards the versatility of new drugs.

Europe, Switzerland, Novartis AG, NVTSY, Gleevec (Medication)

---

Web site is a prelude to Glaxo's OTC weight-loss pill

Article Abstract:

GlaxoSmithKline PLC has introduced a Web site offering diet advice, in anticipation of approval of Alli, its new over-the-counter diet pill, by the Food and Drug Administration. The Web site, QuestionEverything.com, does not mention any GlaxoSmithKline drugs . If approved, Alli will be the first FDA licensed over-the-counter diet pill in the U.S.

United Kingdom, Product introduction, Services introduction, New Products/Services, Company Web site/Web page, Web sites (World Wide Web), Web sites, Company service introduction, Service introduction, Weight reducing preparations, Anti-obesity agents, GlaxoSmithKline PLC, Alli (Medication)

---

Sanofi aims to sell obesity drug this year, despite FDA setback

Article Abstract:

Sanofi-Aventis S.A. of France is still planning to sell its new anti-obesity drug, rimonabant later in 2006 although the United States Food and Drug Administration has decided to delay approval, requesting more information. Projected sales for the drug could be as high as $3.5 billion to $5 billion per year.

Product development, France, Company Profile, SNY, Sanofi-Aventis S.A., Rimonabant (Medication)

Similar abstracts:

• Abstracts: Glaxo aims to boost prospects of four promising cancer drugs. Britain stirs outcry by weighing benefits of drugs versus price
• Abstracts: Credit Agricole's profit rose 9.8 percent in fourth quarter. BNP profit rises, boosted by retail, investment units
• Abstracts: Olex plots submarine surprise! Turkish seiners for France. Surface drive helps 'halve fuel costs'
• Abstracts: Ryanair prices offset fuel costs as profit soars. Ryanair expects profit drop on fuel costs
• Abstracts: As Mexico's oil giant struggles, its laws block foreign help

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.